

IDEXX LABORATORIES INC /DE  
Form 8-K  
November 15, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **November 9, 2016**

**IDEXX LABORATORIES, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

**000-19271**

**01-0393723**

*(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)  
of incorporation)*

One IDEXX Drive, Westbrook, Maine **04092**

*(Address of principal executive offices) (ZIP Code)*

**207.556.0300**

*(Registrant's telephone number, including area code)*

Not Applicable

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 9, 2016, IDEXX Laboratories, Inc. (the “Company”) announced that Michael Williams, Ph.D., Executive Vice President, will be leaving the Company in February 2017 and is stepping down from his current position effective November 9, 2016. Dr. Williams will remain employed at the Company until February 28, 2017 in order to assist in the transition of his responsibilities. In connection with this, the Company agreed to pay Dr. Williams a lump sum of \$460,000, the amount of \$450,000 in 26 bi-weekly installments, and certain other benefits, all in consideration of Dr. Williams’s agreement to certain non-competition and non-solicitation obligations and a standard release of claims.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IDEXX LABORATORIES, INC.**

Date: November 15, 2016 By: /s/ Jacqueline L. Studer  
Jacqueline L. Studer  
Corporate Vice President, General  
Counsel and Secretary